PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference

BOSTON, Sept. 01, 2023 -- PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe...

Related Keywords

Washington ,District Of Columbia ,United States ,New York ,Canada ,Ottawa ,Ontario ,Boston ,Massachusetts ,James Mcarthur ,Sarah Sutton ,Ashling Holland ,Laurence Watts ,Preclinical Development ,Pepgen Inc ,Preclinical Development At Pepgen ,Nasdaq ,Gilmartin Group ,Myotonic Dystrophy Foundation Annual Conference ,Study Support Continued Development ,Head Of Clinical Development ,Dystrophy Foundation Annual Conference ,Neuromuscular Disease Meeting ,Annual Global Investment Conference ,Investor Relations ,Industry Updates Part ,Potomac Ballroom ,Michelle Mellion ,Senior Vice President ,Support Phase ,Continue Evaluating Safety ,Duchenne Muscular Dystrophy ,Positive Results ,Enhanced Delivery Oligonucleotide ,Private Securities Litigation Reform Act ,Markets ,